Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
|Articles|April 26, 2011
COMING SOON...
Our coverage from the Academy of Managed Care Pharmacy's 23rd Annual Meeting & Showcase.
Advertisement
Coverage from the Academy of Managed Care Pharmacy’s 23rd Annual Meeting & Showcase. Our reporting from the conference will include video interviews with thought leaders and coverage of special healthcare reform implementation issues, payment reform, care delivery, coverage requirements, comparative effectiveness research, and more.
Don’t miss our as-they-happen highlights from the nation’s premier event regarding managed care pharmacy.
Advertisement
Related to this article
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Physicians to Discuss 2026 Oncology Care Index at Patient-Centered Oncology Care®, Premier Annual AJMC® Event Starting Today in Nashville |
60% of Community Physicians Say Clinical Trial Options Are Limited; 93% Say Pragmatic Designs Would Help
Advertisement
Advertisement
Trending on AJMC
1
Tavapadon for Parkinson Disease Approved by FDA
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Health System Pharmacies Keep Patients on GLP-1 Therapy
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5